PGR and breast carcinoma: To further determine the clinical pertinence of NLGN2 in breast cancer, we assessed its prognostic performance in different intrinsic subtypes with or without the estrogen receptor (ER), progesterone receptor (PR) and Erb-B2 receptor tyrosine kinase 2 (HER2) expression.